Shokken

Shokken is a biotechnology company developing a proprietary platform for the oral delivery of biologics, which are traditionally administered via injection. The company's initial focus is on developing an oral version of GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity. By overcoming the challenges of gastrointestinal degradation and poor absorption, Shokken aims to improve patient compliance and access to life-changing peptide and protein therapies. The technology leverages advanced delivery systems to protect sensitive molecules through the digestive tract and facilitate their entry into the bloodstream.